Showing results (21-30 of 58) with videos related to

Sort By:
Pageof 6
International Immunopharmacology|February 16, 2026
Inhibition of ROCK2 impedes osteoclastogenesis through Src-Ca2+-NFATc1 signaling pathway and alleviates ovariectomy-induced bone lossQin Yang, Jianchao Chen, Lihong Li, et al.
Pharmacological Research|August 15, 2025
Osteoclast precursor cell-derived Flot2 is a novel therapeutic target for bone loss diseasesBinhua Zou, Jiehuang Zheng, Weili He, et al.
Cell Stem Cell|November 7, 2025
Tissue regeneration: Unraveling strategies for resolving pathological fibrosisJiao Li, Shuyong Wang, Jie Yuan, et al.
Biochemical Pharmacology|March 7, 2026
A resveratrol derivative RVX-208 inhibits PD-1/PD-L1 to restrain non-small cell lung cancer as an immunotherapyZiye Chen, Ruopeng Li, Fengsheng Chen, et al.
Biochemical Pharmacology|February 15, 2026
An allosteric SHP2 inhibitor suppresses breast cancer-induced osteoclastogenesis and bone lysisQinghe Liang, Wenqi Dai, Jiehuang Zheng, et al.
Frontiers in Medicine|June 24, 2025
Heterotaxy polysplenia syndrome with cholangiopancreatic cancer: a case report and literature reviewZiye Chen, Yu-Ann Chen, Xuedong Wang, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|February 5, 2026
Hexahydrocurcumin inhibits osteoclastogenesis and bone destruction in osteoporosis by targeting c-SrcLihong Li, Wenqi Dai, Zhuwei Zhong, et al.
Journal of Advanced Research|March 31, 2024
Erianin serves as an NFATc1 inhibitor to prevent breast cancer-induced osteoclastogenesis and bone destructionJiehuang Zheng, Weili He, Yan Chen, et al.
Cancer Biology & Medicine|September 14, 2019
Cytosolic phospholipase A2α modulates cell-matrix adhesion via the FAK/paxillin pathway in hepatocellular carcinomaPiao Guo, Yuchao He, Lu Chen, et al.
Pageof 6